Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Hankil Son"'
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 58:121-127
Background and objective Varenicline is an effective drug for smoking cessation. The aim of the present study was to compare the pharmacokinetics and safety profiles of two different varenicline formulations (varenicline tartrate (reference) and vare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::655b111ef8bff984ba328aa43ca89ff9
https://doi.org/10.5414/cp203574
https://doi.org/10.5414/cp203574
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. 122:139-148
Telmisartan, an angiotensin receptor blocker (ARB), is indicated for the treatment of essential hypertension. This study aimed to develop a mechanistic model of telmisartan drug effect in human using non-invasive markers. Data were acquired from a pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9a7a3e2e6bf8585abaebc9705204705
https://doi.org/10.1111/bcpt.12856
https://doi.org/10.1111/bcpt.12856
Autor:
Kweon Sik Min, Hankil Son, Nam Cheol Park, Jina Jung, Tai Young Ahn, Ji-Kan Ryu, Seung Wook Lee, Sae Woong Kim, Ki Hak Moon, Kwangsung Park, Dae Yul Yang, Sung Won Lee, Du Geon Moon, Jae Seog Hyun, Jong Kwan Park, Soo Woong Kim, Sang-Kuk Yang
Publikováno v:
The Journal of Sexual Medicine. 14:1018-1027
Background Phosphodiesterase type 5 inhibitors and α-adrenergic blocking agents (α-blockers) are widely used for the treatment of erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b5fa1eae23c6c4611b8ed346f09668d
https://doi.org/10.1016/j.jsxm.2017.06.006
https://doi.org/10.1016/j.jsxm.2017.06.006
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. 120:270-277
Megestrol acetate, an appetite stimulant with low bioavailability, shows increased bioavailability when taken together with food. However, the pharmacokinetic characteristics of megestrol acetate and its relation with food are not well understood. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cefdb2fcafb70ea85dc6a97908b09c6a
https://doi.org/10.1111/bcpt.12677
https://doi.org/10.1111/bcpt.12677
Autor:
Ikhyun Jun, Mary Hongying Cheng, Eunji Sim, Jinsei Jung, Bong Lim Suh, Yonjung Kim, Hankil Son, Kyungsoo Park, Chul Hoon Kim, Joo-Heon Yoon, David C. Whitcomb, Ivet Bahar, Min Goo Lee
Publikováno v:
The Journal of Physiology. 594:2929-2955
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2b2da22ea72a47863d33fd64ef17eaa
https://doi.org/10.1113/jp271311
https://doi.org/10.1113/jp271311
Autor:
Yukyung Kim1,2, Hankil Son1,2, Mijeong Son1,2, Donghwan Lee3, Young-A Heo1,2, Kyungsoo Park1,2 kspark@yuhs.ac
Publikováno v:
Translational & Clinical Pharmacology. 2015, Vol. 23 Issue 1, p31-34. 4p.
Aims Recombinant tissue plasminogen activator (rt-PA) is the only first-line agent approved by the US Food and Drug Administration to treat acute ischaemic stroke. However, it often causes the serious adverse event (AE) of haemorrhagic transformation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ed424fdb96b4ef8b8e3e0012ff38cf
https://europepmc.org/articles/PMC6177699/
https://europepmc.org/articles/PMC6177699/
Publikováno v:
Translational and Clinical Pharmacology
Solifenacin is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms. Solifenacin tartrate is a newly developed salt formulation of solifenacin. This study compared the pharmacokinetic and safety properties after sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a584c2fd1df87cf6fc257972f6d3fb1
https://pubmed.ncbi.nlm.nih.gov/32055552
https://pubmed.ncbi.nlm.nih.gov/32055552
Autor:
Donghwan Lee, Hyerang Roh, Hankil Son, Seong Bok Jang, Seoungoh Lee, Su Youn Nam, Kyungsoo Park
Publikováno v:
Clinical Therapeutics. 36:1171-1181
Rosuvastatin is indicated for hypercholesterolemia or dyslipidemia and metformin mainly for type 2 diabetes. These 2 drugs are frequently prescribed in combination due to the high comorbidity of the 2 diseases. However the nature of pharmacokinetic i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20a3abacc6e328b083cd9325b980800a
https://doi.org/10.1016/j.clinthera.2014.06.004
https://doi.org/10.1016/j.clinthera.2014.06.004
Autor:
Jinju Guk, Hyerang Roh, Su Youn Nam, Yukyung Kim, Mijeong Son, Kyungsoo Park, Donghwan Lee, Hankil Son, Seong Bok Jang
Publikováno v:
Clinical Therapeutics. 36:1147-1158
Purpose Rosuvastatin is indicated for hypercholesterolemia or dyslipidemia and metformin mainly for type 2 diabetes. These 2 drugs are frequently prescribed in combination due to the high comorbidity of the 2 diseases. However the nature of pharmacok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f35e5118087a89a7f3e875f3b5f12aa
https://doi.org/10.1016/j.clinthera.2014.06.007
https://doi.org/10.1016/j.clinthera.2014.06.007